Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy

J Pediatr Hematol Oncol. 2014 Nov;36(8):e549-52. doi: 10.1097/MPH.0000000000000162.

Abstract

We present a case of inadvertent high-dose therapy with temozolomide in a child with recurrent diffuse intrinsic pontine glioma followed by a rapid clinical response. The patient was a 7-year-old boy who initially presented with a history of left facial palsy, double vision, headache, and ataxia. His symptoms were completely resolved following radiotherapy but recurred 3 months after. Following recurrence, he received temozolomide in a dose >3 times higher than prescribed inadvertently but tolerated well with a rapid clinical response. He eventually deteriorated after he was substituted with a lower dose of temozolomide and died.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Alkylating / administration & dosage*
  • Brain Stem Neoplasms / drug therapy*
  • Brain Stem Neoplasms / pathology
  • Child
  • Dacarbazine / administration & dosage
  • Dacarbazine / analogs & derivatives*
  • Dose-Response Relationship, Drug
  • Fatal Outcome
  • Glioma / drug therapy*
  • Glioma / pathology
  • Humans
  • Male
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Temozolomide

Substances

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide